Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antengene SCLC trispecific antibody
- Development stage
- Preclinical
- Lead developer
- Antengene
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Antengene's undisclosed trispecific antibody for small cell lung cancer (SCLC) is a therapeutic candidate developed using the company's proprietary **AnTenGager™ TCE 2.0 platform**. As a T-cell engager (TCE), the antibody is designed to bridge T-cells with tumor cells, facilitating targeted immune-mediated destruction of the cancer. While the specific tumor-associated antigens targeted by this molecule have not been publicly disclosed, the trispecific format typically allows for enhanced binding specificity or the incorporation of costimulatory domains to improve the therapeutic window and anti-tumor activity. The program is currently in the preclinical stage of development as part of Antengene's broader portfolio of multi-specific biologics.
- Other names
- Antengene-undisclosed-trispecific antibody-SCLC
02
Targets
DLL3 (Delta-like ligand 3)LAG3 (Lymphocyte activation Gene-3 protein)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on Antengene SCLC trispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antengene SCLC trispecific antibody.